Aclaris Therapeutics, Inc.·4

Apr 9, 4:50 PM ET

Tullman Stephen A. 4

4 · Aclaris Therapeutics, Inc. · Filed Apr 9, 2018

Insider Transaction Report

Form 4
Period: 2018-04-06
Transactions
  • Purchase

    Common Stock

    2018-04-06$16.54/sh+26,700$441,618157,507 total
Holdings
  • Common Stock

    (indirect: By Trust)
    394,014
Footnotes (3)
  • [F1]The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018.
  • [F2]This transaction was executed in multiple trades at prices ranging from $16.23 to $17.06, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  • [F3]These shares are held by the 2007 Irrevocable Trust of Stephen A. Tullman, for which the reporting person's spouse serves as the trustee.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION